MY178327A - Methods and biocompatible compositions to achieve sustained drug release in the eye - Google Patents

Methods and biocompatible compositions to achieve sustained drug release in the eye

Info

Publication number
MY178327A
MY178327A MYPI2017700768A MYPI2017700768A MY178327A MY 178327 A MY178327 A MY 178327A MY PI2017700768 A MYPI2017700768 A MY PI2017700768A MY PI2017700768 A MYPI2017700768 A MY PI2017700768A MY 178327 A MY178327 A MY 178327A
Authority
MY
Malaysia
Prior art keywords
medicament
eye
methods
treating
drug release
Prior art date
Application number
MYPI2017700768A
Other languages
English (en)
Inventor
Shikha P Barman
Moli Liu
Koushik Barman
Kevin L Ward
Brendan Hackett
Original Assignee
Integral Biosystems Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Integral Biosystems Llc filed Critical Integral Biosystems Llc
Publication of MY178327A publication Critical patent/MY178327A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
MYPI2017700768A 2014-09-06 2015-09-08 Methods and biocompatible compositions to achieve sustained drug release in the eye MY178327A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462046918P 2014-09-06 2014-09-06

Publications (1)

Publication Number Publication Date
MY178327A true MY178327A (en) 2020-10-08

Family

ID=55440434

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2017700768A MY178327A (en) 2014-09-06 2015-09-08 Methods and biocompatible compositions to achieve sustained drug release in the eye

Country Status (12)

Country Link
US (2) US9931306B2 (enExample)
EP (1) EP3188688B1 (enExample)
JP (2) JP7026507B2 (enExample)
KR (1) KR102456032B1 (enExample)
CN (2) CN106604695B (enExample)
AU (2) AU2015311637B2 (enExample)
CA (1) CA2960213C (enExample)
ES (1) ES2900025T3 (enExample)
MY (1) MY178327A (enExample)
SG (1) SG11201701714RA (enExample)
WO (1) WO2016037169A1 (enExample)
ZA (2) ZA201701467B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9931306B2 (en) * 2014-09-06 2018-04-03 Integral Biosystems Llc Methods and biocompatible compositions to achieve sustained drug release in the eye
US11458041B2 (en) * 2015-10-08 2022-10-04 Ocular Therapeutix, Inc. Punctal plug and bioadhesives
EP4046609B1 (en) * 2016-09-30 2025-02-26 Mati Therapeutics Inc. Ophthalmic drug sustained release formulation and uses thereof
EP3630024B1 (en) * 2017-05-22 2022-04-06 California Institute of Technology Small molecule transport device with anti-condensation filler for drug delivery or waste removal
CN111050754A (zh) * 2017-07-17 2020-04-21 商福溪生技有限公司 用于递送活性剂的微粒制剂
JP7373207B2 (ja) * 2018-03-01 2023-11-02 バー‐イラン、ユニバーシティー 眼の状態の矯正に使用するためのシステム、方法、及び材料組成物
AU2019280534B2 (en) * 2018-06-05 2022-04-07 Corneat Vision Ltd. A synthetic ophthalmic graft patch
CN109853054A (zh) * 2019-02-27 2019-06-07 上海交通大学医学院附属第九人民医院 一种同轴静电纺丝三维打印生物支架的装置及搭建方法
EP3701974B1 (en) * 2019-02-28 2024-08-28 Agency for Science, Technology and Research A material suitable for use as a vitreous substitute and related methods
KR20210135560A (ko) 2019-03-05 2021-11-15 에어리 파마슈티컬즈, 인코포레이티드 안구 질환 또는 장애를 치료하는 약학 조성물
EP3946458A4 (en) * 2019-04-02 2023-01-11 Cytomatrix Limited COMPOSITION FOR DELIVERY OF BIOLOGICALLY ACTIVE INGREDIENTS AND USES THEREOF
TWI826685B (zh) 2019-05-02 2023-12-21 瑞士商愛爾康公司 可溶解聚合物眼睛插入物及其使用方法
BR112022007332A2 (pt) 2019-10-24 2022-07-05 E Labombard Denis Dispositivo ocular, métodos, composição, caixa para conter e dispensar um dispositivo ocular e kit
CN114760987A (zh) * 2019-12-10 2022-07-15 爱尔康公司 具有可生物降解聚合物的可溶解性聚合物眼睛插入物
EP4142664A4 (en) * 2020-04-27 2024-05-29 Ocular Therapeutix, Inc. METHODS FOR TREATING ALLERGIC CONJUNCTIVITIS
KR102467288B1 (ko) * 2020-06-09 2022-11-17 동국대학교 산학협력단 결막 접촉용 약물 전달기
EP3928805A1 (en) * 2020-06-26 2021-12-29 Royal College of Surgeons in Ireland A device for use in the delivery of an active agent
US20220160668A1 (en) * 2020-11-23 2022-05-26 Sight Sciences, Inc. Formulations and methods for treating conditions of the eye
US20240261218A1 (en) * 2021-05-26 2024-08-08 The Texas A&M University System Biodegradable mucoadhesive pharmaceutical formulations and methods thereof
CN114869862A (zh) * 2022-04-24 2022-08-09 温州医科大学附属眼视光医院 一种带引流功能的青光眼手术缓释抗瘢痕膜及制备方法
WO2025050106A1 (en) * 2023-08-31 2025-03-06 University Of Tennessee Research Foundation Sustained release ocular implants
WO2025255203A1 (en) * 2024-06-06 2025-12-11 Ocular Therapeutix, Inc. Compositions and methods for treating ocular diseases

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5026559A (en) * 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
US5177168A (en) 1989-10-17 1993-01-05 Polymer Technology Corp. Polymeric compositions useful in oxygen permeable contact lenses
CA2202511A1 (en) * 1994-10-12 1996-04-25 Laurence A. Roth Targeted delivery via biodegradable polymers
US8273366B2 (en) 2002-06-05 2012-09-25 University Of Florida Research Foundation, Incorporated Ophthalmic drug delivery system
US8003124B2 (en) * 2005-04-08 2011-08-23 Surmodics, Inc. Sustained release implants and methods for subretinal delivery of bioactive agents to treat or prevent retinal disease
CA2843097C (en) 2005-05-24 2015-10-27 Inspire M.D Ltd. Stent apparatuses for treatment via body lumens and methods of use
CN101511317A (zh) * 2006-09-28 2009-08-19 Sca卫生用品公司 吸收性物品、带结构、带结构制造方法和吸收性物品制造方法
US8614103B2 (en) * 2006-10-27 2013-12-24 Lpath, Inc. Compositions and methods for treating sphingosine-1-phosphate (S1P) related ocular diseases and conditions
AR063619A1 (es) * 2006-12-18 2009-02-04 Alcon Res Ltd Dispositivos y metodos para la administraicion de un farmaco oftalmico
US8974814B2 (en) * 2007-11-12 2015-03-10 California Institute Of Technology Layered drug delivery polymer monofilament fibers
US8083347B2 (en) * 2008-04-29 2011-12-27 Ocugenics, LLC Drug delivery system and methods of use
US8361492B2 (en) 2008-04-29 2013-01-29 Ocugenics, LLC Drug delivery system and methods of use
US20100104654A1 (en) * 2008-10-27 2010-04-29 Allergan, Inc. Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
US20100291182A1 (en) * 2009-01-21 2010-11-18 Arsenal Medical, Inc. Drug-Loaded Fibers
JP5890182B2 (ja) 2009-02-12 2016-03-22 インセプト エルエルシー ヒドロゲルプラグによる薬物送達
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
US8961600B2 (en) * 2009-06-25 2015-02-24 Optonol Ltd. Method of using a fiber matrix for maintaining space in soft tissues
CN102821753A (zh) 2010-01-22 2012-12-12 阿勒根公司 前房内持续释放治疗药植入物
US20110229551A1 (en) * 2010-03-17 2011-09-22 Notus Laboratories, Inc. Drug delivery compositions and methods using nanofiber webs
US9028860B2 (en) * 2010-04-28 2015-05-12 Poly-Med, Inc. Partially microcellular, selectively hydrophilic composite construct for ocular drug delivery
WO2012114138A1 (fr) * 2011-02-21 2012-08-30 Cerebel-Invest Sa Implants biodégradables pour la libération contrôlée sous-conjonctivale d'une molécule active
US20120276186A1 (en) 2011-04-29 2012-11-01 Ghebremeskel Alazar N Sustained release latanoprost implant
JP5989780B2 (ja) 2011-09-14 2016-09-07 フォーサイト・ビジョン５・インコーポレイテッドＦｏｒｓｉｇｈｔ Ｖｉｓｉｏｎ５，Ｉｎｃ． 眼挿入装置および方法
CN203089455U (zh) * 2013-02-01 2013-07-31 浙江大学医学院附属第二医院 襻上镶嵌有药物缓释微囊的人工晶状体
US9931306B2 (en) * 2014-09-06 2018-04-03 Integral Biosystems Llc Methods and biocompatible compositions to achieve sustained drug release in the eye

Also Published As

Publication number Publication date
ES2900025T3 (es) 2022-03-15
JP2022001582A (ja) 2022-01-06
ZA201701467B (en) 2018-04-25
KR20170052582A (ko) 2017-05-12
AU2015311637B2 (en) 2019-07-18
US10328033B2 (en) 2019-06-25
WO2016037169A1 (en) 2016-03-10
EP3188688A1 (en) 2017-07-12
EP3188688A4 (en) 2018-07-25
AU2019250153B2 (en) 2021-02-04
CN109481447A (zh) 2019-03-19
EP3188688B1 (en) 2021-11-03
US20180280313A1 (en) 2018-10-04
US20170296483A1 (en) 2017-10-19
CN106604695B (zh) 2018-10-23
CA2960213C (en) 2023-03-28
AU2019250153A1 (en) 2019-10-31
KR102456032B1 (ko) 2022-10-18
JP2017526655A (ja) 2017-09-14
US9931306B2 (en) 2018-04-03
AU2015311637A1 (en) 2017-03-23
CA2960213A1 (en) 2016-03-10
SG11201701714RA (en) 2017-04-27
CN106604695A (zh) 2017-04-26
JP7026507B2 (ja) 2022-02-28
NZ729467A (en) 2024-04-26
ZA201705792B (en) 2018-12-19

Similar Documents

Publication Publication Date Title
MY178327A (en) Methods and biocompatible compositions to achieve sustained drug release in the eye
MX2018014763A (es) Suministro intraocular de farmacos.
WO2014165308A3 (en) Microsphere drug delivery system for sustained intraocular release
BR112015006929A2 (pt) sistemas de distribuição de droga biodegradável para liberação sustentada de proteínas
WO2011084366A3 (en) Compositions and drug delivery systems for intraocular delivery of sirna molecules, their use for treating conditions
PH12019500423A1 (en) Pharmaceutical composition
MX2017009037A (es) Compuestos espiro triciclicos.
WO2014179568A3 (en) Two-layer ocular implant
PH12017501097A1 (en) Sunitinib formulations and methods for use thereof in treatment of ocular disorders
EA201590902A1 (ru) Способы и устройства, применяемые для лечения глазных болезней у человека
MX390100B (es) Suspension acuosa que contiene nanoparticulas de glucocorticosteroide.
PH12016500869B1 (en) Methods of treatment of ocular conditions with a sustained drug delivery implant
PH12013501579A1 (en) Androgen composition for treating an opthalmic condition
UY36465A (es) Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico
CO2017002494A2 (es) N-alquilaril-5-oxiaril-octahidro ciclopenta[c]pirrol moduladores alostéricos negativos de nr2b
EP4324454A3 (en) Cross-linking agents and associated methods
CL2020001183A1 (es) Implantes de liberación sostenida para reducir la presión intraocular con duración prolongada del efecto.
EA201490721A1 (ru) Лекарственное средство для лечения заболеваний передней камеры глаза, включающее ребамипид и агент, удерживающий слезы
MX375963B (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
HK1232159A1 (zh) 用於矫正老视的药理学眼科用组合物和其施用
MX2020011536A (es) Deposito de liquido para liberacion sostenida no invasiva de agentes al ojo.
IN2014DN09713A (enExample)
UY33562A (es) Agonistas de receptores de bradicinina y su utilización para el tratamiento de la hipertensión ocular y el glaucoma
WO2016069950A3 (en) Methods of treating hypoxia-associated optical conditions with cartilage oligo matrix protein-angiopoietin 1 (comp-ang1)
JOP20190137A1 (ar) مستحضر لطب العيون